CompanyGraph
Sequent Scientific Ltd.
SEQUENT · NSE India · India
sequent.inFinancials as of FY2025 · latest on file
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2025 (year ended March 31, 2025). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
105.01BINR1.09B · vs all stocks (USD)
Trailing P/E
123.42xRevenue (TTM)
16.58BINR172.77M · vs all stocks (USD)
Profit Margin
2.52%Beta
0.9640xvs all stocks
52-Week Change
30.42%vs all stocks
Market Capitalization
105.01BINR1.09B · vs all stocks (USD)
Enterprise Value
55.23BINR575.52M · vs all stocks (USD)
Trailing P/E
123.42xForward P/E
39.84xPEG Ratio
0.2304xPrice to Sales (TTM)
5.29xPrice to Book (MRQ)
6.21xEnterprise to Revenue
3.33xEnterprise to EBITDA
30.04xGross Margin
54.46%Profit Margin
2.52%Operating Margin
9.66%Return on Assets (TTM)
4.91%Return on Equity (TTM)
6.64%Revenue (TTM)
16.58BINR172.77M · vs all stocks (USD)
Revenue per Share (TTM)
65.96INRUpdated Sep 29, 2026Quarterly Revenue Growth
15.00%Gross Profit (TTM)
7.82BINR81.53M · vs all stocks (USD)
EBITDA (TTM)
3.36BINR34.99M · vs all stocks (USD)
Net Income (TTM)
418.08MINR4.36M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
464.80%Operating Cash Flow (TTM)
1.04BINR10.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-14.90MINR-155.25K · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
658.88MINRFY2025 · Mar 31, 2025Revenue
15.47BINRFY2025 · Mar 31, 2025Cost of Goods Sold
8.64BINRFY2025 · Mar 31, 2025Gross Profit
6.83BINRFY2025 · Mar 31, 2025Operating Income
1.19BINR12.40M · vs all stocks (USD)
Pre-tax Income
443.06MINRFY2025 · Mar 31, 2025Income Tax Expense
120.47MINRFY2025 · Mar 31, 2025Net Income
322.59MINRFY2025 · Mar 31, 2025EBIT
1.00BINRFY2025 · Mar 31, 2025EBITDA (Income Statement)
1.63BINRFY2025 · Mar 31, 2025Selling, General & Administrative
893.95MINRFY2025 · Mar 31, 2025Other Operating Expenses
1.20BINRFY2025 · Mar 31, 2025Non-operating Interest Income
27.24MINRFY2025 · Mar 31, 2025Non-operating Interest Expense
559.56MINRFY2025 · Mar 31, 2025EPS (Basic)
0.8800INRFY2025 · Mar 31, 2025EPS (Diluted)
0.8500INRFY2025 · Mar 31, 2025Basic Shares Outstanding
249.38MSharesFY2025 · Mar 31, 2025Diluted Shares Outstanding
249.38MSharesFY2025 · Mar 31, 2025Minority Interests (P&L)
-103.81MINRFY2025 · Mar 31, 2025Preferred Stock Dividends
0.00INRFY2025 · Mar 31, 2025Operating Cash Flow
360.47MINRFY2025 · Mar 31, 2025Free Cash Flow
66.60MINRFY2025 · Mar 31, 2025Cash & Cash Equivalents (End of Period)
626.60MINRFY2025 · Mar 31, 2025Starting Profit (CF Statement)
443.06MINRFY2025 · Mar 31, 2025Stock-based Compensation
324.10MINRFY2025 · Mar 31, 2025Other Non-cash Items
541.41MINRFY2025 · Mar 31, 2025Change in Accounts Receivable (CF)
-479.40MINRFY2025 · Mar 31, 2025Change in Other Assets/Liabilities
-468.70MINRFY2025 · Mar 31, 2025Capital Expenditures
-293.87MINRFY2025 · Mar 31, 2025Other Investing Activity
-20.00KINRFY2025 · Mar 31, 2025Net Investing Cash Flow
-293.89MINRFY2025 · Mar 31, 2025Long-term Debt Issuance
2.68BINRFY2025 · Mar 31, 2025Long-term Debt Payments
-1.88BINRFY2025 · Mar 31, 2025Net Short-term Debt Issuance
-828.90MINRFY2025 · Mar 31, 2025Net Financing Cash Flow
48.38MINRFY2025 · Mar 31, 2025Shares Outstanding
435.72MSharesUpdated Sep 29, 2026Float Shares
96.00MSharesUpdated Sep 29, 2026% Held by Insiders
68.03%vs all stocks
% Held by Institutions
7.40%vs all stocks
Total Cash (MRQ)
709.00MINR7.39M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.84INRUpdated Sep 29, 2026Total Debt (MRQ)
4.90BINR51.10M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5531xCurrent Ratio (MRQ)
1.91xBook Value per Share (MRQ)
32.38INRUpdated Sep 29, 2026Total Assets
16.02BINR166.94M · vs all stocks (USD)
Total Current Assets
8.74BINRFY2025 · Mar 31, 2025Total Liabilities
8.32BINRFY2025 · Mar 31, 2025Total Non-current Assets
7.28BINRFY2025 · Mar 31, 2025Total Non-current Liabilities
3.27BINRFY2025 · Mar 31, 2025Total Current Liabilities
5.05BINRFY2025 · Mar 31, 2025Cash
611.71MINRFY2025 · Mar 31, 2025Cash Equivalents
14.89MINRFY2025 · Mar 31, 2025Cash & Cash Equivalents
626.60MINRFY2025 · Mar 31, 2025Other Short-term Investments
5.44MINRFY2025 · Mar 31, 2025Accounts Receivable
3.63BINRFY2025 · Mar 31, 2025Inventory
3.85BINRFY2025 · Mar 31, 2025Accounts Payable
2.57BINRFY2025 · Mar 31, 2025Short-term Debt
1.81BINRFY2025 · Mar 31, 2025Other Current Liabilities
214.50MINRFY2025 · Mar 31, 2025Long-term Debt
3.00BINRFY2025 · Mar 31, 2025Common Stock (Book)
500.60MINRFY2025 · Mar 31, 2025Retained Earnings
1.25BINRFY2025 · Mar 31, 2025Total Shareholders' Equity
7.70BINR80.28M · vs all stocks (USD)
Treasury Stock
24.72MINRFY2025 · Mar 31, 202552-Week Low
178.13INRUpdated Sep 29, 202652-Week High
298.00INRUpdated Sep 29, 202652-Week Change
30.42%vs all stocks
Beta
0.9640xvs all stocks
50-Day MA
208.71INRUpdated Sep 29, 2026200-Day MA
193.44INRUpdated Sep 29, 2026Avg 10-Day Volume
762.00KSharesUpdated Sep 29, 2026Avg 30-Day Volume
791.57KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
1.63INRUpdated Sep 29, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tandem Diabetes Care Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Artivion Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wandong Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangzhou Wondfo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiuzhitang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Hongyu Wuzhou Medica Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Seegene, Inc.
Tier 1ProductionApproval-Gated PipelineRule